EUVIMEDEUVIMED entdecken
Crossref

Hemodynamic and Clinical Outcomes of Transcatheter Valve Expansion in Degenerated Mitral Bioprostheses

Mark J Zorman iD, Kaleb Foster, Bas L Kietselaer iD, Mayra E Guerrero iD, Charanjit S Rihal iD, Mackram F Eleid iD

Circulation: Cardiovascular Interventions · 2026-07 · 19 (7)

DOI: 10.1161/circinterventions.125.016270 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Circulation: Cardiovascular Interventions, 2026-07. Verfasst von Mark J Zorman und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN. Hauptthemen laut MEDLINE: Bioprosthesis, Mitral Valve, Heart Valve Prosthesis, Transcatheter Mitral Valve Replacement. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Transcatheter mitral valve-in-valve replacement is an established therapy for intermediate and high-risk patients with degenerated bioprostheses, but restricted transcatheter valve (THV) expansion within rigid surgical frames and elevated gradients have raised durability concerns. This study aimed to evaluate midterm outcomes of mitral valve-in-valve patients according to THV expansion and sizing strategy. METHODS: Patients who underwent mitral valve-in-valve with balloon-expandable valves at Mayo Clinic Rochester between 2014 and 2023 were retrospectively analyzed. THV expansion (inflow, waist, outflow) was measured from procedural fluoroscopy and indexed to nominal size, with zero indicating expansion to nominal dimensions. Median index values were used as subgroup cutoffs to compare the incidence of the primary composite outcome of all-cause mortality, heart failure readmission, and valve reintervention. RESULTS: The analysis included 80 patients with a median follow-up of 2.5 years. A total of 53 (66%) valves were underexpanded across all 3 sizes, with median inflow, waist, and outflow expansion indices of −10.2, −16.2, and −3.2, respectively. Across all indices, THV expansion closer to nominal size was associated with lower rates of the primary outcome ( P

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BioprosthesisMitral ValveHeart Valve ProsthesisTranscatheter Mitral Valve ReplacementProsthesis FailureHemodynamicsHeart Valve Prosthesis ImplantationHumansProsthesis DesignTreatment OutcomeRetrospective StudiesFemaleMaleTime FactorsAgedRisk FactorsAged, 80 and overRecovery of Function

Stichwörter der Autor:innen

bioprosthesismitral valveprosthesis failuretranscatheter mitral valve replacement

Autor:innen und Institutionen

  • Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN.

ORCID-Profile: Mark J Zorman, Bas L Kietselaer, Mayra E Guerrero, Charanjit S Rihal, Mackram F Eleid

Zitieren

APA

Zorman, M. J., Foster, K., Kietselaer, B. L., Guerrero, M. E., Rihal, C. S., & Eleid, M. F. (2026). Hemodynamic and Clinical Outcomes of Transcatheter Valve Expansion in Degenerated Mitral Bioprostheses. Circulation: Cardiovascular Interventions, 19(7). https://doi.org/10.1161/circinterventions.125.016270

Vancouver

Zorman MJ, Foster K, Kietselaer BL, Guerrero ME, Rihal CS, Eleid MF. Hemodynamic and Clinical Outcomes of Transcatheter Valve Expansion in Degenerated Mitral Bioprostheses. Circulation: Cardiovascular Interventions. 2026;19(7). doi:10.1161/circinterventions.125.016270

BibTeX
@article{Zorman2026,
  author = {Zorman, Mark J and Foster, Kaleb and Kietselaer, Bas L and Guerrero, Mayra E and Rihal, Charanjit S and Eleid, Mackram F},
  title = {Hemodynamic and Clinical Outcomes of Transcatheter Valve Expansion in Degenerated Mitral Bioprostheses},
  journal = {Circulation: Cardiovascular Interventions},
  year = {2026},
  volume = {19},
  number = {7},
  doi = {10.1161/circinterventions.125.016270}
}
Kostenlos starten →